Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115200 | 0.85 | FABP4 (0.46) | FABP4ALDH1A1TBXA2RCDC25ACDC25B | |
| SCHEMBL5117224 | 0.84 | FABP4 (0.51) | FABP4ALDH1A1TBXA2RCDC25ACDC25B | |
| SCHEMBL5111162 | 0.81 | CDC25A (0.45) | FABP4ALDH1A1CDC25ACDC25BGAA | |
| SCHEMBL493617 | 0.78 | KMT2A (0.42) | ALDH1A1TBXA2RGAAPOLBKMT2A | |
| SCHEMBL11237701 | 0.78 | ALDH1A1 (0.63) | FABP4ALDH1A1TBXA2RCDC25ACDC25B | |
| SCHEMBL5113650 | 0.75 | FABP4 (0.47) | FABP4ALDH1A1TBXA2RCDC25ACDC25B | |
| SCHEMBL6763992 | 0.74 | POLB (0.47) | ALDH1A1GAAPOLBKMT2A | |
| SCHEMBL11888774 | 0.74 | GAA (0.41) | GAAPOLBKMT2A | |
| SCHEMBL5115187 | 0.71 | KMT2A (0.41) | ALDH1A1GAAPOLBKMT2A | |
| SCHEMBL5115190 | 0.71 | KMT2A (0.41) | ALDH1A1GAAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | FABP4 2346/4885ALDH1A1 73/4885TBXA2R 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.